Trial Profile
A Phase I/II Trial of the Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat assessing Efficacy and Safety in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 25 Jan 2016 New trial record
- 08 Dec 2015 Interim results (n=42) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology